NASDAQ:OPTN - OptiNose Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.78 -0.23 (-2.87 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$8.01
Today's Range$7.75 - $8.07
52-Week Range$7.33 - $30.00
Volume220,342 shs
Average Volume209,933 shs
Market Capitalization$333.12 million
P/E Ratio-1.38
Dividend YieldN/A
Beta-0.57
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPTN
Previous Symbol
CUSIPN/A
Phone267-364-3500

Debt

Debt-to-Equity Ratio0.51
Current Ratio10.44
Quick Ratio10.13

Price-To-Earnings

Trailing P/E Ratio-1.38
Forward P/E Ratio-2.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$47.50 million
Price / Sales6.75
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.09 per share
Price / Book1.90

Profitability

EPS (Most Recent Fiscal Year)($5.63)
Net Income$-48,900,000.00
Net MarginsN/A
Return on Equity-67.95%
Return on Assets-41.63%

Miscellaneous

Employees82
Outstanding Shares41,230,000
Market Cap$333.12 million
OptionableNot Optionable

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How were OptiNose's earnings last quarter?

OptiNose Inc (NASDAQ:OPTN) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.11. The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.57 million. View OptiNose's Earnings History.

When is OptiNose's next earnings date?

OptiNose is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for OptiNose.

What price target have analysts set for OPTN?

3 brokerages have issued 1 year target prices for OptiNose's stock. Their forecasts range from $27.00 to $30.00. On average, they anticipate OptiNose's share price to reach $28.3333 in the next year. This suggests a possible upside of 263.2% from the stock's current price. View Analyst Price Targets for OptiNose.

What is the consensus analysts' recommendation for OptiNose?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

What are Wall Street analysts saying about OptiNose stock?

Here are some recent quotes from research analysts about OptiNose stock:
  • 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (8/15/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating research coverage of OPTN stock with an Overweight rating and 12-month PT of $30. We view Xhance as an asset that will create significant share value and allow the company to expand commercial activities into ENT- and allergist-managed medical conditions. We believe OPTN should be able to leverage the proprietary exhalation delivery system (EDS) to develop therapies that fit within the target physician population and could be applicable for other medical uses that could create partnering/out-licensing opportunities." (8/7/2018)

Has OptiNose been receiving favorable news coverage?

Press coverage about OPTN stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OptiNose earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of OptiNose's key competitors?

Who are OptiNose's key executives?

OptiNose's management team includes the folowing people:
  • Mr. Peter K. Miller, CEO & Director (Age 57)
  • Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 53)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
  • Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)
  • Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), JPMorgan Chase & Co. (4.55%), JPMorgan Chase & Co. (4.55%), Foresite Capital Management IV LLC (3.54%), Thrivent Financial for Lutherans (3.11%) and BlackRock Inc. (2.61%). Company insiders that own OptiNose stock include Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

Which major investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Wells Fargo & Company MN and TIAA CREF Investment Management LLC. View Insider Buying and Selling for OptiNose.

Which major investors are buying OptiNose stock?

OPTN stock was bought by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Foresite Capital Management IV LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Rice Hall James & Associates LLC, Point72 Asset Management L.P., Massachusetts Financial Services Co. MA and Citadel Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $7.80.

How big of a company is OptiNose?

OptiNose has a market capitalization of $333.12 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is http://www.optinose.com.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]


MarketBeat Community Rating for OptiNose (NASDAQ OPTN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  288
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel